These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 32436445)
1. Potential specific therapies in COVID-19. Gul MH; Htun ZM; Shaukat N; Imran M; Khan A Ther Adv Respir Dis; 2020; 14():1753466620926853. PubMed ID: 32436445 [TBL] [Abstract][Full Text] [Related]
2. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Uzunova K; Filipova E; Pavlova V; Vekov T Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Zhong H; Wang Y; Zhang ZL; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW Pharmacol Res; 2020 Jul; 157():104872. PubMed ID: 32360583 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial. Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849 [TBL] [Abstract][Full Text] [Related]
5. Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Martinez MA Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826 [TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Mehta N; Mazer-Amirshahi M; Alkindi N; Pourmand A Am J Emerg Med; 2020 Jul; 38(7):1488-1493. PubMed ID: 32336586 [TBL] [Abstract][Full Text] [Related]
7. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. Wang D; Li Z; Liu Y J Infect Public Health; 2020 Oct; 13(10):1405-1414. PubMed ID: 32684351 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. Costanzo M; De Giglio MAR; Roviello GN Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571 [TBL] [Abstract][Full Text] [Related]
9. A global treatments for coronaviruses including COVID-19. Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467 [TBL] [Abstract][Full Text] [Related]
10. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial. Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468 [TBL] [Abstract][Full Text] [Related]
14. Psychopharmacology of COVID-19. Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246 [TBL] [Abstract][Full Text] [Related]
17. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. Vargas M; Servillo G; Einav S Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567 [TBL] [Abstract][Full Text] [Related]
18. COVID-19: A review of the proposed pharmacological treatments. Lam S; Lombardi A; Ouanounou A Eur J Pharmacol; 2020 Nov; 886():173451. PubMed ID: 32768505 [TBL] [Abstract][Full Text] [Related]
19. Antiviral therapy for coronavirus disease 2019. Gong S; Su J; Yan X; Li F; Hu L; Liu S Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 May; 45(5):598-602. PubMed ID: 32879113 [TBL] [Abstract][Full Text] [Related]
20. The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Hazafa A; Ur-Rahman K; Haq IU; Jahan N; Mumtaz M; Farman M; Naeem H; Abbas F; Naeem M; Sadiqa S; Bano S Drug Metab Rev; 2020 Aug; 52(3):408-424. PubMed ID: 32546018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]